Strategies for planning GMP compliant Vaccine Manufacturing Sites

摘要

,,Vaccines are expected to be very safe" is one of the headlines in the presentation of the CBER ,,Vaccine safety team". However, ensuring this expected safety is one of the greatest challenges for manufacturers: new vaccines are needed for diseases for which no vaccine is available yet, and almost always they are needed quickly. So what's the solution for this,,dilemma"?